New drug combo targets Hard-to-Treat prostate cancer
NCT ID NCT02522715
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can lower PSA levels, a marker of cancer activity. About 37 participants are enrolled in this early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
-
Portland VA Medical Center
Portland, Oregon, 97239, United States
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- New PET tracer could reveal hidden prostate cancer
- New hope for advanced bladder cancer? bevacizumab combo tested
- Intermittent fasting tested to ease radiation side effects in cancer patients
- Supercharged immune cells take on Hard-to-Treat prostate cancer